Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation

[1]  Yanhong Li,et al.  Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation , 2014, Journal of Translational Medicine.

[2]  Yu Zhao,et al.  AML1–ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia , 2014, The FEBS journal.

[3]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[4]  K. Tsui,et al.  Metallothionein 3: An androgen‐upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells , 2013, The Prostate.

[5]  A. Samadani,et al.  DNA Methylation and Cancer Development: Molecular Mechanism , 2013, Cell Biochemistry and Biophysics.

[6]  F. Xing,et al.  The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML) , 2013, BMC Medical Genetics.

[7]  Yanhong Li,et al.  Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells , 2012, BMC Cancer.

[8]  J. Persson,et al.  DNA methylation in ATRA-treated leukemia cell lines lacking a PML-RAR chromosome translocation. , 2012, Anticancer research.

[9]  S. Armstrong,et al.  Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. , 2012, Trends in immunology.

[10]  F. Xing,et al.  Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays , 2012, Cancer Cell International.

[11]  A. Kohlmann,et al.  Landscape of TET2 mutations in acute myeloid leukemia , 2012, Leukemia.

[12]  S. Armstrong,et al.  Targeting epigenetic programs in MLL-rearranged leukemias. , 2011, Hematology. American Society of Hematology. Education Program.

[13]  Naimei Tang,et al.  Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.

[14]  Haojie Huang,et al.  FOXO1: a potential target for human diseases. , 2011, Current drug targets.

[15]  M. Monsalve,et al.  The complex biology of FOXO. , 2011, Current drug targets.

[16]  Zhao Wen Li,et al.  Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663 , 2011, Journal of hematology & oncology.

[17]  Feng Wang,et al.  Metallothionein 3 attenuated the apoptosis of neurons in the CA1 region of the hippocampus in the senescence-accelerated mouse/PRONE8 (SAMP8). , 2011, Arquivos de neuro-psiquiatria.

[18]  J. Koh,et al.  Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes , 2010, Molecular Brain.

[19]  T. Fukagawa,et al.  KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. , 2010, Cancer research.

[20]  R. Chung,et al.  Neuronal growth‐inhibitory factor (metallothionein‐3): evaluation of the biological function of growth‐inhibitory factor in the injured and neurodegenerative brain , 2010, The FEBS journal.

[21]  D. Tindall,et al.  FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.

[22]  V. Schramm,et al.  A Transition State Analogue of 5′-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck Cancers* , 2007, Journal of Biological Chemistry.

[23]  S. Koschmieder,et al.  DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. , 2007, Cancer research.

[24]  J. Issa,et al.  PML-RARα and AML1–ETO translocations are rarely associated with methylation of the RARβ2 promoter , 2006, Annals of Hematology.

[25]  B. Aronow,et al.  beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. , 2006, Cancer research.

[26]  J. Issa,et al.  PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. , 2006, Annals of hematology.

[27]  A. Ruszkiewicz,et al.  Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation , 2005, Molecular Cancer.

[28]  Amornpan Ajjimaporn,et al.  Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells , 2005, Brain Research Bulletin.

[29]  R. Palmiter,et al.  Role of metallothionein-III following central nervous system damage , 2003, Neurobiology of Disease.

[30]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[31]  J. Ji,et al.  Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. , 2003, Carcinogenesis.

[32]  Rakesh Nagarajan,et al.  FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.

[33]  M. Bartolomei,et al.  Epigenetic reprogramming in the mammalian embryo: struggle of the clones , 2002, Genome Biology.

[34]  P. Guldberg,et al.  In-tube DNA methylation profiling by fluorescence melting curve analysis. , 2001, Clinical chemistry.

[35]  M. Toyota,et al.  Methylation profiling in acute myeloid leukemia. , 2001, Blood.

[36]  C. Willman.  Targeted AML therapy: new biologic paradigms and therapeutic opportunities , 2001, Leukemia.

[37]  M. Loda,et al.  Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN , 2000, Molecular and Cellular Biology.

[38]  E. Estey,et al.  NCCN Practice Guidelines for Acute Myelogenous Leukemia. , 2000, Oncology.

[39]  Rudolf Jaenisch,et al.  DNA hypomethylation leads to elevated mutation rates , 1998, Nature.

[40]  A. Olek,et al.  A modified and improved method for bisulphite based cytosine methylation analysis. , 1996, Nucleic acids research.

[41]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.